PORTFOLIO

PORTFOLIO COMPANIES

Celaid Therapeutics Inc.

  • President & CEO:
    Nobuyuki Arakawa

URL:https://www.celaidtx.com/

COMPANY PROFILE

Regenerative medicine start-up aiming to develop next-generation cell therapy products using human hematopoietic stem cell expansion technology

Celaid Therapeutics provides products and services that utilize human hematopoietic stem cell (HSC) expansion technology. Their focuses are research and discovery support for media/reagents, developing cell therapy products for HSC transplantation, and cell therapy products combined with gene-editing technology.

COMPANY STORY

Origin

Prof. Satoshi Yamasaki from Tsukuba University and Hiromitsu Nakauchi from the University of Tokyo's Institute of Medical Science (also a Professor at Stanford University) successfully developed a technology using PVA, a component of liquid glue, for the large-scale in vitro expansion of mouse hematopoietic stem cells. They aim to apply this technology in cell therapy for clinical use in humans.

Strength

In vitro expansion of human HSC has been difficult until now. The conventional cell growth media, containing biological substances such as albumin and cytokine, carry problems such as low reproducibility, difficulty in quality control, and high cost of raw materials. Our technology enabled in vitro expansion of human HSC in an albumin/cytokine-free medium, which allows easy quality control and cost reduction. In addition, since HSC can be expanded regardless of the source (bone marrow, umbilical cord blood, peripheral blood), application to various diseases can be expected.

UTEC’s value add

Understanding the innovation of technology, providing financial support from the seed phase to facilitate commercialization. Assistance in formulating business strategies and development plans, finding and introducing talent, and supporting legal and intellectual property matters.
  • Succeeded in large-scale expansion of mouse HSC in vitro

  • Succeeded in large-scale expansion of human HSC in vitro

  • Large-scale ex vivo expansion of human HSC can be expected for clinical applications to various diseases

STORY LIST